Response plan
Unofficial · descriptive, not a forecast. Antimicrobial resistance is tracked through periodic modeled estimates and surveillance reports, not a live data feed — every figure here is dated and cited. Not for clinical or prescribing decisions; consult clinicians and official guidance.

Antimicrobial ResistanceThe global & U.S. burden of drug-resistant bacteria and fungi — the "silent pandemic" — and an emerging-resistance watch

Global: GRAM/IHME · 2019 burden, 2050 projection U.S.: CDC AR Threats · 2019 report modeled study estimate interpretive curated watch
● Global burden modeled
Deaths attributable to bacterial AMR · 2019
—
deaths that would not have happened if infections were drug-susceptible
Deaths associated with bacterial AMR · 2019
—
deaths where a drug-resistant infection played a role
Projected attributable deaths · per year by 2050
—
GRAM forecast; ~39M cumulative deaths 2025–2050
Attributable death rate by region, per 100,000 (2019) — the burden falls hardest on low- and middle-income regions.
Six leading pathogens accounted for ~73% of attributable deaths (~929,000). Attributable deaths, 2019:
Source: GRAM — Murray et al., The Lancet 2022 (global bacterial AMR burden, 2019) and GBD 2021 AMR Collaborators, The Lancet 2024 (trends & 2050 projection). These are modeled estimates with wide uncertainty intervals; the central values are shown. "Attributable" and "associated" are two distinct counterfactual measures — both are reported because each answers a different question.
▦ U.S. threats — the CDC list modeled
Antibiotic-resistant infections · U.S. per year
—
plus C. difficile, ~223,900 cases — together >3 million infections
Deaths · U.S. per year
—
~48,000 including C. difficile
CDC ranks 18 resistant pathogens + C. difficile by threat level. Estimated U.S. infections & deaths per year (most figures 2017):
Source: CDC, Antibiotic Resistance Threats in the United States, 2019. Tiers: urgent serious concerning watch. Estimates are modeled and are due to be refreshed by CDC; treat them as orders of magnitude, not exact counts.
⚠ Emerging-resistance watch interpretive
Resistance mechanisms and organisms spreading faster than the headline reports capture. Curated from CDC, WHO and published surveillance — qualitative early-warning, not a live count.
Compiled from CDC, WHO and peer-reviewed surveillance; reflects status as of the date below. Candida auris clinical-case figures are CDC surveillance counts (a rare AMR threat that is nationally reported) and show the steep recent rise; other entries are qualitative. Naloxone-style note: many of these have few or no remaining reliable treatments, which is what makes them "urgent".
◍ What drives it — & the broken pipeline interpretive
Interpretive synthesis of the scientific consensus (CDC, WHO, O'Neill Review 2016). AMR is a natural evolutionary process accelerated by how antimicrobials are used in people, animals and agriculture; the response combines stewardship, infection prevention, surveillance, and new drug/vaccine development.